Relevant and even prescient commentary on news, politics and the economy.

The economics of rare disease therapies

I came of age scientifically at the beginning of the cloning era. As various genes associated with human genetic disorders—sickle cell disease, cystic fibrosis, muscular dystrophy, Huntington’s—were cloned, the papers reporting these successes always ended with some statement that now the door was open to therapy. These prophecies proved to be wildly optimistic. Now, with […]